Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in Advanced Solid Tumors
NCT06534762Phase 2Recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirabegron in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), colorectal cancer (CRC), pancreatic cancer (PC), triple-negative breast cancer (TNBC), sponsored by Zhejiang Provincial People's Hospital. Started Jul 2024; status: recruiting.
02
Drugs
mirabegron
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)colorectal cancer (CRC)pancreatic cancer (PC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06534762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534762.